Drug Profile
CX 717
Alternative Names: Ampakine® CX717; CX-717Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Cortex Pharmaceuticals
- Developer Cortex Pharmaceuticals; National Institute of Drug Abuse; RespireRx Pharmaceuticals
- Class 2 ring heterocyclic compounds; Antidementias; Morpholines; Nootropics; Oxadiazoles; Small molecules
- Mechanism of Action AMPA receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Attention-deficit hyperactivity disorder; Respiratory insufficiency
- No development reported Spinal cord injuries; Substance-related disorders
- Discontinued Alzheimer's disease; Sleep disorders